Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Pro Medicus Limited ( (AU:PME) ) has provided an update.
Pro Medicus Limited has notified the market of the issue of 40,358 unquoted performance rights under its employee incentive scheme, with an issue date of 28 August 2024. The move underscores the company’s ongoing use of equity-based remuneration to align staff incentives with long-term shareholder value, while not affecting the free float as the securities are not intended to be quoted on the ASX.
The most recent analyst rating on (AU:PME) stock is a Buy with a A$350.00 price target. To see the full list of analyst forecasts on Pro Medicus Limited stock, see the AU:PME Stock Forecast page.
More about Pro Medicus Limited
Pro Medicus Limited is an Australian-listed healthcare technology company that develops and supplies medical imaging IT solutions, including radiology information systems and picture archiving and communication systems, primarily for hospitals, imaging centres and other diagnostic service providers.
Average Trading Volume: 171,510
Technical Sentiment Signal: Hold
Current Market Cap: A$21.96B
See more data about PME stock on TipRanks’ Stock Analysis page.